Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics

• DOI: 10.20944/preprints202212.0013.v1
• Publication Date: 2022-12-01T17:58:15Z
• Authors: Kyle T. Gustafson; Negin Mokhtari; Elise C. Manalo; Jose Montoya Mira; Austin Gower; Ya-San Yeh; Mukanth Vaidyanathan; Sadik C. Esener; Jared Fischer
• Keywords: PLGA; Biomolecule; Biocompatible material; Zeta potential; Glycolic acid

Some cancer cells rely heavily on non-essential biomolecules for survival, growth, and proliferation. Enzyme based therapeutics can eliminate these biomolecules, thus specifically targeting neoplastic cells; however, enzyme are susceptible to immune clearance, exhibit short half-lives, require frequent administration. Encapsulation of therapeutic cargo within biocompatible biodegradable poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) is a strategy controlled release. Unfortunately, PLGA NPs burst release shortly after delivery or upon introduction aqueous environments where they decompose via hydrolysis. Here we show the generation hybrid silica-coated (SiLGA) as viable drug vehicles exhibiting sub-200 nm diameters, metastable Zeta potential, high loading efficiency content. Compared uncoated NPs, SiLGA offer greater retention enzymatic activity slow cargo. Thus, encapsulation enzymes, such asparaginase, could reduce frequency administration, increase half-life, improve efficacy patients with range diseases.